CoChat

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

Open access
Das, Satya, Johnson, Douglas B. · 2019 · Journal for ImmunoTherapy of Cancer

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index; 28 of the 148 sources its claims cite were checked for support.

Abstract

Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with many advanced malignancies, only 15-60% of patients respond, leaving a broad swath of patients who do not derive benefit. Identifying biomarkers to optimally identify patients who will benefit from ICIs is a major research focus for the oncology community. Thus far, predictive biomarker research has focused on tumor signatures such as microsatellite instability, programmed death-ligand 1 (PD-L1) expression and tumor mutational burden; clinical biomarkers have been far less studied. One potential clinical biomarker for ICI response in patients is immune-related adverse event (IRAE) onset.IRAEs are thought to represent bystander effects from activated T-cells and it is plausible that patients responding to ICIs would have greater likelihood of autoimmune toxicities (e.g. due to a more competent/treatment-responsive immune system, or cross-reactivity between tumor and host tissue). Earlier studies in melanoma patients however, suggested no association between IRAE onset and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody efficacy. In contrast, a growing body of literature suggests IRAE onset is predictive of anti-programmed cell death protein 1 (PD-1) and anti-PD-L1 antibody response across a variety of solid tumors. Most of these studies report that patients who experienced IRAEs demonstrate marked improvements in progression-free survival, overall survival and overall response rate compared to those lacking toxicity.Key questions regarding the association between IRAE onset and ICI efficacy remain. The most pertinent of these involve whether the association is only relevant for patients treated with anti-PD-1 and anti-PD-L1 antibodies and whether IRAE site, severity, timing of onset and management influence ICI efficacy. Herein, we discuss the seminal studies which have begun to address these questions and have shaped the narrative about the predictive value of IRAE onset for patients on ICIs, in this review.

Overview

CoChat Summary

TL;DR

This narrative review synthesizes evidence that immune-related adverse event (IRAE) onset is associated with improved anti-tumor efficacy of anti-PD-1 and anti-PD-L1 antibodies across many solid tumors, while the association with anti-CTLA-4 antibodies is less uniform. It discusses mechanisms, IRAE site/severity/timing/management, and efforts to uncouple autoimmunity from anti-tumor response.

Key findings

  • Across anti-PD-1/PD-L1 studies, IRAE onset was generally associated with better outcomes: in 270 metastatic NSCLC patients, OS was not reached vs 8.21 months (HR 0.29; 95% CI 0.18–0.46; p = .001) and PFS 5.2 vs 1.97 months (HR 0.42; 95% CI 0.32–0.57; p < .001); in 195 nivolumab-treated NSCLC patients, ORR was 43.5% vs 10%, PFS 5.7 vs 2.0 months (HR 0.41), and OS 17.8 vs 4.0 months (HR 0.33). Similar associations were reported in RCC, UCC, gastrointestinal, gastric, and HNSCC studies, e.g., HNSCC ORR 30.6% vs 12.3%, PFS 6.9 vs 2.1 months, OS 12.5 vs 6.8 months.
  • Anti-CTLA-4 data are mixed: positive studies reported ORR 36% vs 5% for grade 3/4 IRAEs and ORR 26% vs 2% with any IRAE, but other melanoma analyses found no differences in time to treatment failure or OS, and one phase I/II study found no significant IRAE–DCR association (p = .45) except grade 3/4 IRAEs in the highest-DCR cohort (p = .03).
  • IRAE severity generally did not correlate with efficacy; timing findings were inconsistent; corticosteroid management mostly did not worsen outcomes, though high-dose glucocorticoids for ipilimumab-induced hypophysitis were associated with reduced survival, and baseline corticosteroids appeared to dampen responses.
  • Proposed mechanisms include shared tumor/tissue antigens, gut microbiome composition, and IL-6; uncoupling strategies discussed include GM-CSF, IL-6 blockade, and a terminated trial combining nivolumab/ipilimumab with vedolizumab and plozalizumab.

Methods

  • Narrative review of seminal studies, focused on patient populations with FDA-approved ICI indications and ICIs used alone (no chemotherapy combinations) to improve generalizability.
  • Data discussed include studies across NSCLC, melanoma, RCC, UCC, gastrointestinal, gastric, and HNSCC cancers, with anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies; Table 1 summarizes outcomes by IRAE presence.
  • Main analysis is qualitative synthesis of ORR, PFS, OS, DCR, and time-to-next-treatment according to IRAE presence, site, severity, timing, and management; no new primary data are reported.

Limitations

  • The paper states that many questions remain about whether IRAE site, severity, timing, and management influence ICI efficacy, and that prospective well-powered studies are needed; mechanisms linking toxicity and response are not fully apparent.
  • The paper notes possible guarantee-time bias and confounding by time on therapy, and states that the importance of various microbial species remains far from clear and that large series comparing corticosteroid doses are needed.
  • Evident from the text: this is a narrative review, not a systematic review or meta-analysis, and it relies heavily on retrospective studies and some conference abstracts, with heterogeneous disease sites, agents, and outcome definitions.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s40425-019-0805-8

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Mechanisms of Response Dependent and Response Independent Autoimmune Toxicity from Immune Checkpoint Inhibitors. On top left is a depiction of myocardial cells expressing shared antigens with the tumor which leads to autoimmunity. On bottom left is a depiction of IL-6 production from T-cell activation resulting in attack on enterocytes. On top right is a depiction of encephalitis as a result of an anti-viral response being unleashed by ICI treatment. On bottom right is a depiction of endogenous CTLA-4 expression on the pituitary gland leading to T-cell attack after anti-CTLA-4 treatment. Abbreviations: APC, antigen presenting cell; TCR, T-cell receptor; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; Ag, antigen; MHC, major histocomptability complex; Pit, pituitary gland
Fig. 1 Mechanisms of Response Dependent and Response Independent Autoimmune Toxicity from Immune Checkpoint Inhibitors. On top left is a depiction of myocardial cells expressing shared antigens with the tumor which leads to autoimmunity. On bottom left is a depiction of IL-6 production from T-cell activation resulting in attack on enterocytes. On top right is a depiction of encephalitis as a result of an anti-viral response being unleashed by ICI treatment. On bottom right is a depiction of endogenous CTLA-4 expression on the pituitary gland leading to T-cell attack after anti-CTLA-4 treatment. Abbreviations: APC, antigen presenting cell; TCR, T-cell receptor; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; Ag, antigen; MHC, major histocomptability complex; Pit, pituitary glandCC BY · PubMed Central

Verification

Claims the paper makes

16 Valid · 1 Not valid · 110 Not checked · 19 Own results and interpretations

114 more claims · 11 with their cited sources checked

Create a free account to see all 146 claims and to verify the 120 references still open.

See all claims — free account
  • It may state two separate claims as one. 21
  • Probably not a substantial claim. 7
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 64 references

Research works printed but not linked: 1

  1. Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26(36):5950–6. · DOI · Paper page

Cited by

See all 1,145

Metadata

Authors
Das, S., & Johnson, D. B.
Affiliations
Vanderbilt University (US)
Corresponding author
Das, Satya
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2019-11-15
Volume
7
Issue
1
Pages
306-306
ISSN
2051-1426 (ISSN-L)
OpenAlex
W2988124258
Cited by
1,145
References
64
Citations by year
2026: 121 · 2025: 173 · 2024: 198 · 2023: 185 · 2022: 198 · 2021: 174 · 2020: 95
FWCI
11.14
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Foundation for the National Institutes of Health (5 K12 CA90625-19, K23 CA204726)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
immune-related adverse events, immune checkpoint inhibitors, predictive biomarkers, anti-PD-1, PD-L1 inhibitors, anti-CTLA-4 antibody, antitumor efficacy, immune-related pneumonitis, immune-related colitis, immune-related endocrinopathy, immune-related encephalitis, immune-related hepatitis, immune-related hypophysitis, immune-related nephritis, immune-related skin toxicity
MeSH terms
Antineoplastic Agents, Immunological, Animals, Humans, Neoplasms, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. https://app.cochat.ai/papers/10.1186/s40425-019-0805-8
The paper
Das, S., & Johnson, D. B. (2019). Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-019-0805-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.